The Food and Drug Administration announced last week that it would not regulate “IRB shopping,” a practice in which sponsors of clinical trials choose to submit proposed research to institutional review boards that they believe will approve it. The FDA said it had concluded that such choosiness either does not occur or is not a significant problem.
Many large universities and higher-education groups had criticized the idea of new rules, saying they would bog down institutional review boards in paperwork without providing additional protection for research subjects. But advocates for those research volunteers say the practice, even if it cannot be quantitatively documented, is real and worrisome because it could allow ethically suspect studies to avoid adequate oversight.
We’re sorry, something went wrong.
We are unable to fully display the content of this page.
This is most likely due to a content blocker on your computer or network.
Please allow access to our site and then refresh this page. You may then be asked to log in, create an account (if you don't already have one), or subscribe.
If you continue to experience issues, please contact us at 202-466-1032 or help@chronicle.com.